Ampligen Showing Promise for Recurrent Ovarian Cancer in Phase 1/2 Trial, Phase 2 Study Now Recruiting

Ampligen Showing Promise for Recurrent Ovarian Cancer in Phase 1/2 Trial, Phase 2 Study Now Recruiting
Hemispherx Biopharma's experimental therapy Ampligen (rintatolimod) can change the tumor microenvironment to increase the amount of infiltrating T-cells, an approach that is showing promise in a Phase 1/2 clinical trial for recurrent ovarian cancer, according to the company. Funded in part by an Ovarian Cancer Specialized Program of Research Excellence from the National Institutes of Health, the study is being conducted at the University of Pittsburgh Medical Center. Ampligen — approved in Argentina for severe cases of chronic fatigue syndrome — is an immune modulator that activates part of the immune system and is thought to assist in immune infiltration within tumors. In cellular models, Ampligen promoted an accumulation of killer T-cells, which are immune cells that attack cancerous ones, without attracting regulatory T-cells (T-regs) – potent immunosuppressive cells that promote the progression of cancer through their ability to limit the anti-tumor immune response. Interim results from the Phase 1/2 trial (NCT02432378) showed a similar behavior in ovarian cancer patients, indicating the investigational therapy has the potential to selectively reprogram the tumor microenvironment and induce immune infiltration without intensifying immunosuppressive responses. "Ampligen has the potential to be clinically significant because a robust killer T-cell population in the tumor microenvironment without attracting Tre
Subscribe or to access all post and page content.